Amylx Pharmaceuticals Inc vs Walt Disney Co — how do they compare? Amylx Pharmaceuticals Inc trades at $23.65 (market cap $2.53B), while Walt Disney Co trades at $103.54 (market cap $178.16B). The key difference: Walt Disney Co is far larger — about 70.4× Amylx Pharmaceuticals Inc's market cap, and Walt Disney Co pays a 1.45% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | DIS | |
|---|---|---|
Market Cap | $2.53B | $178.16B |
Sector | Health | Media |
52-Week High | $24.19 | $118.86 |
52-Week Low | $7.82 | $92.40 |
Enterprise Value | $2.28B | $219.02B |
Volume | — | 7,546,013 |
Dividend Yield | — | 1.45% |
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $22.82, down 5.66% on the day, with a bullish technical signal from moving averages and key support at $22. The company reported a net loss of -$144.74M for 2025, with negative ROE and ROA, but holds a $250.8M cash runway into 2028. The pivotal Phase 3 LUCIDITY trial for avexitide is set for a late August/early September 2026 readout, a key near-term catalyst.
Analyst consensus is strongly bullish with a $30.00 price target, though recent earnings misses and negative cash flow from operations in 2026 pose risks. The stock's outlook hinges on successful clinical trial results and the subsequent regulatory pathway for its lead endocrine asset.
Disney (DIS) trades at $103.51, down 1.32% on the day, with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with four consecutive quarterly earnings beats, revenue growth to $94.43B in 2025, and improving profit margins. Recent news highlights advertising opportunities from major events and ongoing FCC regulatory challenges.
Outlook remains positive with analyst consensus target of $126 representing 22% upside potential. Key opportunities include streaming growth and theme park investments, while risks involve regulatory disputes and box office performance variability. Wall Street maintains strong buy sentiment with 62.5% of analysts recommending purchase.
Trailing returns across standard periods
Latest headlines on both assets
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →The Walt Disney Company is an entertainment company with operations in media networks, park experiences & consumer products, studio entertainment and Direct-to-Consumer networks and channels. The Company serves customers worldwide.
Read more on DIS →